Acquisition - May 29, 2013
AstraZeneca acquires Omthera Pharmaceuticals
AstraZeneca has entered into a definitive agreement to acquire Omthera Pharmaeuticals for up to $443m. The specialty pharmaceutical company is based in Princeton, New Jersey, and focuses on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia. The company’s investigational product, EpanovaTM, is aimed at […]